These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 1415446

  • 1. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME.
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [Abstract] [Full Text] [Related]

  • 2. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H.
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [Abstract] [Full Text] [Related]

  • 3. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD.
    Acta Obstet Gynecol Scand Suppl; 1992 Aug; 156():15-21. PubMed ID: 1324552
    [Abstract] [Full Text] [Related]

  • 4. Norgestimate: a clinical overview of a new progestin.
    Bringer J.
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
    Corson SL.
    Acta Obstet Gynecol Scand Suppl; 1990 Jun; 152():25-31. PubMed ID: 2189282
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL.
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [Abstract] [Full Text] [Related]

  • 7. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 May; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 8. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995 May; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

  • 9. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS, Chapdelaine A, Upmalis D, Olson W, Smith J.
    Acta Obstet Gynecol Scand Suppl; 1992 May; 156():9-14. PubMed ID: 1324557
    [Abstract] [Full Text] [Related]

  • 10. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A, Rouffy J, Upmalis D, Dain MP.
    Acta Obstet Gynecol Scand Suppl; 1992 May; 156():33-8. PubMed ID: 1324555
    [Abstract] [Full Text] [Related]

  • 11. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G.
    Int J Fertil Menopausal Stud; 1994 May; 39(5):283-91. PubMed ID: 7820162
    [Abstract] [Full Text] [Related]

  • 12. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A, Stoy DB, LaRosa JC, Muesing RA, Cleary PA, Miller VT, Gilbert PR, Stadel B.
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
    Gauthier A, Upmalis D, Dain MP.
    Acta Obstet Gynecol Scand Suppl; 1992 Aug; 156():27-32. PubMed ID: 1324554
    [Abstract] [Full Text] [Related]

  • 14. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J.
    Int J Fertil; 1991 Aug; 36 Suppl 1():25-31. PubMed ID: 1678378
    [Abstract] [Full Text] [Related]

  • 15. Long-term profile of a new progestin.
    Lippman J.
    Int J Fertil; 1992 Aug; 37 Suppl 4():218-22. PubMed ID: 1362189
    [Abstract] [Full Text] [Related]

  • 16. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN, Liew D, Ratnam SS.
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [Abstract] [Full Text] [Related]

  • 17. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S, Elicio N, Cordera R, Gapitanio GL, Montagna G, Croce S, Saturnino M, Balestreri R, De Cecco L.
    Acta Obstet Gynecol Scand; 1987 Jan; 66(4):327-32. PubMed ID: 2962417
    [Abstract] [Full Text] [Related]

  • 18. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ, Buret J, Gillain D, Romus MA, Lambotte R.
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [Abstract] [Full Text] [Related]

  • 19. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K.
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [Abstract] [Full Text] [Related]

  • 20. Supportive European data on a new oral contraceptive containing norgestimate.
    Becker H.
    Acta Obstet Gynecol Scand Suppl; 1990 Jun; 152():33-9. PubMed ID: 2189283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.